However, I have strong reservations and concerns about self-injection of non-FDA-approved or compounded peptides that carry significant risks, including contamination, dosing errors and serious adverse events such as compartment syndrome (dangerous muscle pressure buildup) that can lead to surgery or even death, as documented by FDA reports
Comment: A few commenters supported the removal of the measure and stated they remain committed to health equity and to operationalizing SDOH screening and intervention in the best manner for their facilities
This is the total amount of lyophilized peptide in the vial, printed on the label commonly 5mg, 10mg, or 15mg for retatrutide research vials
it's scientifically unsound
Was approved with no issues and received product on 12/20
[DOI] [PubMed] [Google Scholar] Berlin 1968 Berlin H, Berlin R, Brante G